India Pharma Outlook Team | Thursday, 28 May 2026
Tata-backed MedTherapy claims a CAR-T breakthrough, marking what could be a major shift in cancer treatment manufacturing.
The company says it can now produce CAR-T therapy within just 24 hours, compared to the several weeks the process usually takes. If successful at scale, the development could help lower treatment costs and improve access to one of the most expensive forms of cancer care available today.
CAR-T therapy is a personalised treatment used mainly for blood cancer treatment, where a patient’s immune cells are modified to recognise and destroy cancer cells. The process involves collecting T-cells from the patient, genetically engineering them in a laboratory, and then reinfusing them into the body to fight the disease.
However, despite its promise, CAR-T treatment remains difficult to access because production often takes four to eight weeks and comes at a very high cost.
Also Read: India Pharma Moves on ESG but Faces Waste, Energy Hurdles
MedTherapy says its new manufacturing platform can reduce this timeline to just one day. According to the company, faster production could be especially important for critically ill patients who may not be able to wait several weeks for treatment. The firm also claims that its technology can lower manufacturing costs significantly, which could eventually make these therapies more affordable in India and support growth in cell and gene therapy.
The company, founded in India in 2020 and backed by Tata Sons, has been working to strengthen capabilities in advanced cancer treatment and biotechnology in India. MedTherapy operates a research and technology centre in Boston and has a manufacturing facility in India’s National Capital Region focused on advanced treatment technologies. Tata Sons is among the company’s major investors and strategic partners.
MedTherapy has partnered with Cipla partnership efforts to bring its blood cancer-focused CAR-T therapy to India. Under the agreement, Cipla is expected to manage branding and commercialisation once the therapy receives the necessary regulatory approvals. The partnership is expected to strengthen India’s role in gene therapy in India and improve access to newer treatment options.
The company’s manufacturing facility in Noida is being positioned as India’s first dedicated gene therapy manufacturing hub. MedTherapy says the site can support treatment for nearly 5,000 patients each year and is already serving both domestic and international programmes.
While the announcement has generated interest, experts say the technology will still need clinical validation and regulatory approvals before it can be widely adopted. Long-term safety, manufacturing consistency, and treatment outcomes will remain important factors.
Still, if the company’s claims prove successful, the breakthrough could help make precision medicine, immunotherapy, and affordable cancer treatment more accessible for patients in the future.
.jpg)
.jpg)
